Amorfix Test for vCJD achieves 100% specificity on 20,000 blood donations in France
Amorfix Life Sciences announced it has tested 20,000 blood donations in France using its EP-vCJD™ blood screening test as part of a large-scale study to demonstrate the feasibility of routine testing of blood donations for vCJD (variant Creutzfeldt-Jakob disease). At the UK specification of a required sensitivity of 1:100,000 dilution of vCJD brain, the Amorfix test was 100% specific with no false positive samples on repeat testing. According to the company, the test performed five times better than required as it was still 100% specific at a sensitivity of 1:500,000 dilution of vCJD brain. At the maximum sensitivity of 1:1,000,000 dilution of vCJD brain, the test was 99.90% specific which exceeds the 99.85% specificity required by the UK Blood Transfusion Service.
Organizations
Other news from the department research and development

Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.